Skip to main content
Free shipping on orders of $100 or more · Excludes IA, NE & SD · 21+

The Other Path · Education & stories

Alpha-1, Your Liver, and Your Lungs: What to Know Before Smoking or Taking Botanicals

Alpha-1, Your Liver, and Your Lungs: What to Know Before Smoking or Taking Botanicals

A genetic condition can connect breathlessness, liver health, and everyday choices about smoke, CBD, THC, kava, kanna, and other herbs. Knowing your genotype can help you ask better questions and protect the organs you rely on.

What if the wheeze that keeps coming back, a family history of emphysema, or an unexplained liver-test result has a genetic connection? Alpha-1 antitrypsin deficiency, often called Alpha-1 or AATD, is an inherited condition that can affect the lungs, liver, or both. Some people first learn about it after years of being treated for more familiar conditions. Others find out through family testing before symptoms develop.

This matters in an apothecary conversation. A plant-derived product can have useful effects and still require extra care when liver or lung disease is present. For people with a Z allele, the goal is to understand their own risk, reduce avoidable exposures, and make decisions with a clinician who knows their history.

The essentials

  • A Z allele can matter, even when there is only one copy. MZ, SZ, and ZZ do not carry identical risks, and genotype does not predict everyone’s outcome.
  • Smoke is an avoidable lung exposure. Tobacco, cannabis, and burning herbs all deserve attention. Candles, incense, and fragrances can also worsen indoor air quality or trigger symptoms.
  • Liver risk and drug metabolism are related but different questions. Having a Z allele does not provide a validated CBD, THC, kava, or kanna dosing formula.
  • Testing is the way to know. COPD, persistent obstructive asthma, unexplained bronchiectasis or liver disease, and a family history are reasons to discuss Alpha-1 testing.

One protein, two very different organ problems

Alpha-1 antitrypsin, or AAT, is a protective protein made mainly in the liver. It circulates in the blood and helps shield lung tissue from enzymes released during inflammation, particularly neutrophil elastase. The gene involved is SERPINA1. [1]

The Z variant changes how AAT folds. Some of the abnormal protein becomes retained and forms polymers inside liver cells instead of being efficiently released. Classic structural research helped explain this accumulation. In susceptible people, it can contribute to liver injury and scarring. At the same time, reduced circulating protection can leave the lungs more vulnerable. [2]

Think of these as two linked mechanisms: too little effective protection reaching the lungs, and potentially harmful protein accumulating in the liver. A person can have liver involvement without obvious lung disease, or lung disease without advanced liver damage. [1]

MZ is a risk genotype, not “just a carrier”

We inherit one SERPINA1 copy from each parent. M generally describes a usual-function allele. MZ means one M and one Z; ZZ means two Z alleles; SZ combines an S and a Z allele. ZZ typically causes much more severe deficiency than MZ. SZ has its own variable risk profile. [1], [3]

Describing MZ as “just a carrier,” with no health consequences, is incorrect. A single Z allele can confer clinically meaningful risk. The Alpha-1 MZ Foundation challenges the long-standing dismissal of MZ individuals and emphasizes that one usual-function M allele does not erase the effects of the Z allele. [4]

The concern involves both organs: abnormal Z protein can accumulate in liver cells, while reduced AAT protection can increase lung vulnerability. Human studies have documented increased liver-disease risk with one Z allele and increased COPD susceptibility in MZ individuals, particularly with smoking exposure. These are reasons to recognize MZ as a health-relevant genotype and investigate symptoms rather than dismiss them. [2], [6], [9]

Anyone with a Z allele should be recognized as having genetic risk, including people with MZ, SZ, or ZZ. The degree of risk differs with the other allele, exposures, coexisting conditions, and individual biology. Being at risk does not mean organ damage is inevitable or already present. It means the result deserves informed prevention, appropriate assessment, and a personalized follow-up discussion, even before symptoms appear. [1], [4]

About that 35-million figure

The Alpha-1 MZ Foundation describes roughly 35 million MZ individuals worldwide. A peer-reviewed epidemiologic paper provides the underlying context: Blanco and colleagues estimated more than 35 million people with the PiMZ genotype across 74 countries with available data. [4], [5]

This is an estimate derived from population studies. It is not a count of 35 million diagnosed patients, and it does not mean that 35 million people have severe ZZ deficiency or symptomatic lung and liver disease. Its importance is that MZ is widespread enough to deserve recognition, informed prevention, and appropriate testing.

What human studies show about MZ risk

  • Liver disease: a UK Biobank analysis found higher odds of cirrhosis in people with one Z allele than in people without the Z allele, with an odds ratio of 1.53. This is a relative association, not a 53% chance of cirrhosis. [6]
  • Additional liver stressors: multicenter research found the Z variant enriched in cirrhosis among people with fatty liver disease or chronic alcohol misuse. This supports taking coexisting liver risks seriously. [7]
  • When cirrhosis already exists: one cohort found faster hepatic decompensation in MZ than MM patients, with a hazard ratio of 1.81. That finding concerns people who already had cirrhosis, not all MZ individuals. [8]
  • Smoking and lungs: a family-based study found greater COPD risk in MZ participants, particularly among those who had smoked. Because the study recruited families around affected people, its risk estimates should not be applied as a universal prediction for every person with MZ. [9]

How does a liver with a Z allele handle CBD, THC, kava, or kanna?

The honest answer begins with three separate questions: What is the genotype? Is liver disease actually present? What product, dose, and combination of medicines is involved? A Z allele is a protein-folding variant in SERPINA1. It is not the same thing as a drug-metabolizing enzyme genotype such as CYP2C9 or CYP2C19. [2], [11], [14]

In the research reviewed here, we did not identify controlled human studies establishing MZ-, SZ-, or ZZ-specific clearance rates or safe retail doses for these botanicals. A person with MZ and preserved liver function should not automatically be treated as having moderate or severe hepatic impairment. Equally, a person with established fibrosis or cirrhosis deserves more than reassurance based on a product being “natural.”

CBD: liver impairment can increase exposure

A phase 1 study gave a single 200-mg dose of purified oral CBD to people with differing degrees of liver impairment. Compared with participants with normal liver function, total CBD exposure was about 2.45 times higher with moderate impairment and 5.15 times higher with severe impairment. These are measures of overall exposure over time, not simply peak intoxication or a genotype-specific multiplier. [11]

Separately, a 2025 randomized trial in healthy adults tested purified CBD at 5 mg/kg/day for 28 days. Liver enzymes rose above three times the upper limit of normal in 5.6% of the CBD group in the reported analysis, versus none receiving placebo. That dose would be 350 mg/day for a 70-kg adult. The result does not establish the same event rate at every retail dose, and participants were not selected for Alpha-1. [12]

What this means: CBD deserves a medication and liver-health review when liver disease is present. Prescription cannabidiol labeling includes liver monitoring, dose adjustments for moderate/severe hepatic impairment, and important interactions. Its dosing rules are medical guidance for that drug, not a do-it-yourself conversion chart for retail oils or gummies. [13]

THC: metabolism, impairment, and smoke are separate issues

Pharmaceutical delta-9 THC, dronabinol, undergoes substantial liver metabolism involving CYP2C9 and CYP3A4, producing an active metabolite, 11-hydroxy-THC. Its labeling describes interactions and adverse effects including impaired thinking, dizziness, and sedation. These are especially relevant to discuss when someone already has significant liver disease or takes sedating medicines. [14]

The evidence does not justify saying that THC invariably poisons an MZ liver. LiverTox has not identified marijuana as a convincing common cause of clinically apparent acute liver injury. That is a different question from safety in advanced liver disease, product interactions, or lung damage from smoking. [15]

What this means: there is no validated “Z-allele THC dose.” Removing smoke does not remove THC’s systemic effects or its need for metabolism. This article discusses THC for education, not as a recommendation or a statement about TOP’s inventory.

Kava: a particular concern when liver disease is present

Kava products have been associated with rare but sometimes severe liver injury, including cases requiring transplantation. Published clinical case analyses support that concern, although case reports cannot establish the risk per cup or per user. [16], [17]

Risk cannot be reduced to “water-based always safe, extracts always dangerous.” NIH notes liver-injury reports involving both solvent-extracted products and water-prepared beverages. Kava also should not be combined with alcohol or other sedating substances. [16]

What this means: if you have Alpha-1-related liver disease, abnormal liver tests, or cirrhosis, avoid self-prescribing kava and discuss it with your liver specialist before use. We do not have an MZ-specific study proving a safe preparation or dose.

Kanna: reassuring findings in healthy adults do not answer the Alpha-1 question

A small randomized trial followed 37 healthy adults receiving a standardized Sceletium tortuosum extract or placebo for three months. Researchers reported no significant changes in hematology or biochemistry measures. This is useful tolerability evidence for that extract in that population. [18]

It does not establish safety in Alpha-1-related liver disease or provide a clearance study for a Z allele. Kanna also has serotonin-reuptake and PDE4-related pharmacology, so combinations with serotonergic medicines, including antidepressants, warrant a pharmacist or prescriber review. A mechanism-based interaction concern is not the same as a measured interaction rate for every product. [19]

Other herbs and mushrooms: use the ingredient list, not the wellness category

“Adaptogen,” “tea,” “nootropic,” and “herbal” do not describe a single liver-safety profile. AASLD guidance documents liver injury associated with a variety of herbal and dietary supplements and highlights problems with mixtures, mislabeling, and identifying the responsible ingredient. [20]

Examples worth bringing to a liver-health review
Ingredient or product Why it matters
Ashwagandha Published case series describe liver injury, including serious outcomes in some patients with pre-existing chronic liver disease. These reports identify a concern, not the percentage of all users affected. [21]
Concentrated green-tea extract The Drug-Induced Liver Injury Network has documented associated liver injury and an HLA genetic association. This concerns a different gene from SERPINA1 and should not be presented as a Z-allele finding. An extract capsule is also a different exposure from a usual cup of tea. [22]
CBG, CBN, CBC, CBDa, THCV CBD’s results cannot simply be transferred to every cannabinoid. We did not identify human Alpha-1 genotype-specific clearance or dosing trials for these ingredients.
Damiana, mullein, lavender, marshmallow, raspberry leaf, reishi, lion’s mane Traditional use or studies for another symptom do not establish safety in MZ, SZ, ZZ, or cirrhosis. Identify the species, plant part, preparation, amount, and all blend ingredients for review. “No specific study found” does not mean “known to be toxic.”

These are examples of questions to ask, not a claim that all herbs cause liver injury. Avoid products promoted as an Alpha-1 cure or a liver “detox.” The clinician needs the actual bottle label and supplement list, including alcohol-containing tinctures and multi-ingredient drinks.

Protect your lungs: avoid smoking and unnecessary indoor combustion

If you have a Z allele, a prudent lung-protection plan is a smoke-free home and avoidance of optional combustion: do not smoke tobacco, cannabis, CBD flower, or herbal blends; choose flameless alternatives to candles, incense, palo santo, and burning sage; and avoid breathing fireplace, wood-stove, or campfire smoke. This is especially important if you also have asthma, COPD, emphysema, or bronchiectasis. It is a risk-reduction recommendation drawn from Alpha-1 research and combustion evidence, not a claim that every exposure causes the same injury in every person. [9], [10], [28], [34], [37]

Why a Z allele makes lung protection important

AAT helps protect lung tissue against destructive enzymes released during inflammation. Tobacco smoke adds inflammatory stress, and experimental research has shown that oxidants from smokers’ alveolar macrophages can inactivate AAT. Human family research also found that smoking markedly increased COPD risk in people with MZ. Protecting the AAT activity and lung reserve you have is a meaningful preventive step. [9], [23]

The strongest genotype-specific evidence concerns tobacco smoking. The recommendation to avoid other combustion sources extends that prevention principle using measured emissions, respiratory research, and existing lung-disease guidance. The evidence supports reducing exposure now, without waiting for a separate clinical trial of every candle, wood, or herb in every Alpha-1 genotype. [10], [28], [34], [35], [37]

Candles and incense measurably pollute indoor air

In a peer-reviewed indoor experiment, Manoukian and colleagues measured both volatile organic compounds (VOCs) and particles from burning candles and incense. VOC concentrations peaked immediately after the burning period, then declined as ventilation and surface interactions removed pollutants. Particle counts rose sharply during combustion, reaching approximately 91,000 particles/cm³ for incense and 220,000 particles/cm³ for candles under the study’s particular conditions. These are particle-number measurements, not TVOC values or PM2.5 mass concentrations, and they do not rank all candles against all incense products. They demonstrate that familiar household flames can create substantial airborne emissions. [35]

There is also human respiratory evidence: a controlled exposure study in people with mild asthma found changes in some airway-related biomarkers after candle emissions. The American Lung Association recommends avoiding scented candles and incense as part of reducing indoor fragrance exposure. For someone protecting vulnerable lungs, decorative flame and fragrance are avoidable exposures. [26], [28]

Sage and palo santo: natural smoke is still smoke

The National Research Council Canada’s technical review of smudging describes particulate matter and combustion irritants, including formaldehyde and acrolein, among the potential by-products of burning natural organic materials such as sage. It also reports elevated fine particles in the limited sage-smudging measurements available. The concentration depends on the material, amount burned, room, and ventilation. Burning an herb does not make its smoke a lung treatment. [36]

Use the same smoke-avoidance approach for palo santo. In an expert indoor-air Q&A hosted by NIEHS, the speaker explains that combustion can introduce harmful chemicals and particles and identifies sage and palo santo burning as likely particle sources. This is a combustion-based recommendation, supported by wood-smoke evidence; it is not a palo-santo-specific clinical trial in people with a Z allele. A calming or meaningful ritual can be preserved without inhaling the smoke. [37], [38]

Wood fires, fireplaces, and campfires belong in the same plan

EPA describes wood smoke as a mixture of gases and fine particles, with pollutants including benzene, formaldehyde, and acrolein. Fine particles can aggravate asthma and trigger attacks. Avoid sitting in smoke from campfires, fire pits, fireplaces, or wood stoves, and reduce smoke entering the home. The concern is inhaled combustion pollution; the exposure varies with the fuel, combustion conditions, ventilation, and distance from the source. [37]

TVOC is useful context, but particles matter too

A rise on a total volatile organic compound (TVOC) monitor can be a warning that indoor air has changed. However, TVOC combines chemicals with very different toxicities, and consumer sensors do not identify every chemical or its dose. Health Canada cautions against using TVOC alone to judge health risk. A low reading also does not rule out fine-particle exposure. For lung protection, consider the source, individual pollutants, and particles, rather than using one TVOC number as permission to keep burning. [39]

Smoking herbs is not a safe substitute

Cannabis smoke contains irritants and many toxic substances also found in tobacco smoke. In longitudinal human research, frequent cannabis use was associated with cough, sputum, and wheeze; reducing or stopping use was associated with symptom improvement. Avoid smoking cannabis, CBD flower, mullein, or other herbal blends, particularly with underlying lung disease. Nicotine-free does not mean combustion-free, and vaping is not a proven safe workaround for diseased lungs. [24], [25], [34]

An edible avoids smoke exposure, but it does not automatically solve liver safety. Oral products still have systemic effects and metabolism. Tinctures are not automatically liver-free, and an absorbed substance is still subject to eventual clearance even when it enters by another route. Ingredient safety and route both matter.

Keep the ritual, protect the air

  • Choose LED or flameless candles instead of a burning wick.
  • Keep sage, palo santo, and other meaningful objects unburned, or choose a smoke-free ritual.
  • Ask household members and visitors to keep smoke away from you and your home.
  • Prefer fragrance-free surroundings if scents trigger symptoms; an essential-oil diffuser avoids combustion but can still release irritating fragrance compounds. [28], [29]
  • Discuss your home, workplace, and recreational exposures with your lung clinician, especially if you have a Z allele plus asthma, COPD, emphysema, or bronchiectasis. [10]

Signs that should put Alpha-1 on the conversation list

Alpha-1 does not have a single telltale symptom, and some people have none. Lung clues include breathlessness with exertion, wheezing, chronic cough with phlegm, recurrent chest infections, or fatigue. Liver clues can include jaundice, persistent itching, or swelling of the abdomen or legs. These symptoms have many possible causes. [30]

Testing becomes especially relevant when a diagnosis is already present:

  • COPD or emphysema: testing is recommended even when smoking history seems to explain the disease.
  • Adult-onset asthma with persistent airflow obstruction: especially when obstruction does not fully reverse with treatment.
  • Unexplained bronchiectasis: chronically widened, damaged airways deserve investigation for an underlying cause.

These indications appear in current respiratory guidance. [32]

Unexplained chronic liver disease or a relative with an abnormal Alpha-1 gene are additional reasons to ask about testing. Age, appearance, and the absence of a family diagnosis should not be used to rule it out. [31]

Do not wait for a genetic test during an emergency. Severe or rapidly worsening breathlessness, vomiting blood, black tarry stools, or new confusion needs urgent medical assessment. New jaundice or abdominal swelling warrants prompt clinical evaluation.

What to ask your clinician after a result

“Do I carry a Z allele?” and “Do I currently have organ damage?” are different questions. Ask what your genotype and AAT level mean together, whether complete lung-function testing is appropriate, and how your liver should be assessed. A normal liver-enzyme panel alone may not settle whether fibrosis is present; a specialist may consider imaging or liver-stiffness testing. [33]

AAT levels can change with inflammation, and levels overlap among genotypes. Guidelines therefore support combining appropriate level and genetic/protein testing rather than relying on an AAT number alone for family testing. Ask for a personalized monitoring plan. Do not assume that MZ automatically requires augmentation infusions; those treatments have specific lung-disease indications. [10]

Bring a full list of prescriptions, over-the-counter medicines, alcohol use, cannabis products, herbs, and supplements. This is useful information for protecting your health, not a reason for judgment. Do not stop prescribed medicines on your own.

The hopeful part: knowing gives you choices

A genetic result is not a prediction that you will lose your lungs or liver. It can provide an opportunity to avoid smoke, investigate unexplained symptoms, address additional liver risks, and help relatives find out whether testing is appropriate. The most helpful wellness choice may be the information that lets you make the next one more safely.

About this article: Educational draft, not a diagnosis, individualized dosing guide, or treatment recommendation. Alpha-1 genotype studies, general liver-impairment research, botanical safety reports, and indoor-air studies answer different questions and are identified accordingly. No product discussed here has been established in this review as a treatment that corrects Alpha-1 deficiency or prevents its organ damage. Literature reviewed through November 15, 2026; this is a focused narrative review, not a systematic review.

Research library and clinical resources

Human studies and primary research are distinguished from practice guidelines, product labels, and patient resources. A case series can identify a possible harm without measuring how often it occurs in all users.

  1. Stoller JK et al., GeneReviews. Alpha-1 Antitrypsin Deficiency.Expert clinical reference: genetics, manifestations, and care
  2. Lomas DA et al. (1992). The mechanism of Z alpha 1-antitrypsin accumulation in the liver. DOI: 10.1038/357605a0.Primary structural/mechanistic research
  3. Alpha-1 Foundation. Alpha-1 Alleles, MZ Status & Genetics.Patient education: genotype and variable risk
  4. Alpha-1 MZ Foundation. Alpha-1 MZ Foundation: MZ genotype information.Patient advocacy resource; prevalence figure checked against the primary epidemiologic paper
  5. Blanco I et al. (2021). Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide. DOI: 10.2147/COPD.S327803.Peer-reviewed prevalence modeling from population studies, not a census of diagnosed patients
  6. Hakim A et al. (2021). Heterozygosity of the Alpha 1-Antitrypsin Pi*Z Allele and Risk of Liver Disease. DOI: 10.1002/hep4.1718.Human genetic association study; UK Biobank and replication
  7. Strnad P et al. (2019). Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. DOI: 10.1136/gutjnl-2018-316228.Human multicenter case-control cohorts, fatty liver and alcohol misuse
  8. Chen VL et al. (2022). Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi*MZ genotype.Human cohort of people who already had cirrhosis; not risk in all MZ individuals
  9. Molloy K et al. (2014). Clarification of the Risk of Chronic Obstructive Pulmonary Disease in α1-Antitrypsin Deficiency PiMZ Heterozygotes. DOI: 10.1164/rccm.201311-1984OC.Family-based human study, smoking and genotype interaction
  10. Sandhaus RA et al. (2016). The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. DOI: 10.15326/jcopdf.3.3.2015.0182.Alpha-1 Foundation/COPD Foundation clinical practice guideline
  11. Taylor L et al. (2019). A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment. DOI: 10.1002/jcph.1412.Human pharmacokinetic study; liver impairment groups, not SERPINA1 genotype groups
  12. Florian J et al. (2025). Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. DOI: 10.1001/jamainternmed.2025.2366.Randomized trial in healthy adults, 5 mg/kg/day for 28 days
  13. DailyMed, U.S. prescribing information. EPIDIOLEX: cannabidiol oral solution.Official label: metabolism, liver monitoring, impairment and drug interactions
  14. DailyMed, U.S. prescribing information. Dronabinol capsules.Official label for pharmaceutical delta-9 THC: metabolism and adverse effects
  15. LiverTox, National Institute of Diabetes and Digestive and Kidney Diseases. Marijuana.Expert assessment of drug-induced liver injury evidence, updated 2023
  16. National Center for Complementary and Integrative Health. Kava: Usefulness and Safety.NIH safety guidance, liver injury and sedating combinations
  17. Stickel F et al. (2003). Hepatitis induced by Kava (Piper methysticum rhizoma). DOI: 10.1016/S0168-8278(03)00175-2.Clinical case analysis; cannot estimate incidence among all users
  18. Nell H et al. (2013). A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. DOI: 10.1089/acm.2012.0185.Small human safety trial, 37 healthy adults; not Alpha-1 or cirrhosis
  19. Terburg D et al. (2013). Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. DOI: 10.1038/npp.2013.183.Human experimental trial plus pharmacologic rationale, not liver-disease safety
  20. Fontana RJ et al. (2023). AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury.Specialist guidance: hepatotoxicity, supplement labeling, and clinical evaluation
  21. Philips CA et al. (2023). Ashwagandha-induced liver injury: A case series from India and literature review.Clinical case series, including pre-existing chronic liver disease; not a frequency estimate
  22. Hoofnagle JH et al. (2021). HLA-B*35:01 and Green Tea Induced Liver Injury. DOI: 10.1002/hep.31538.Drug-Induced Liver Injury Network clinical and genetic study; HLA variant is distinct from SERPINA1
  23. Hubbard RC et al. (1987). Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. DOI: 10.1172/JCI113204.Primary mechanistic research in lung inflammatory cells
  24. Hancox RJ et al. (2015). Effects of quitting cannabis on respiratory symptoms.Human longitudinal cohort with adjustment for tobacco, asthma, sex and age
  25. Centers for Disease Control and Prevention. Cannabis and Lung Health.Public-health synthesis of smoke and respiratory effects
  26. Laursen KR et al. (2023). Airway and systemic biomarkers of health effects after short-term exposure to indoor ultrafine particles from cooking and candles: A randomized controlled double-blind crossover study among mild asthmatic subjects. DOI: 10.1186/s12989-023-00537-7.Controlled human exposure study, short-term biomarkers, not emphysema incidence
  27. PeerJ (2020). Contributions of burning incense on indoor air pollution levels and on the health status of patients with chronic obstructive pulmonary disease. DOI: 10.7717/peerj.9768.Small short-duration observational COPD study; pollution increased without demonstrated short-term lung-function change
  28. American Lung Association. Fragrances.Practical guidance on scented products, candles and incense
  29. U.S. Environmental Protection Agency. Can the use of fragrances indoors cause health impacts?.Official guidance: fragrance-triggered symptoms in susceptible individuals
  30. Alpha-1 Foundation. Symptoms of Alpha-1 Antitrypsin Deficiency.Patient education: lung, liver and skin signs
  31. Alpha-1 Foundation. Testing & Diagnosis.Current testing pathway, confidential ACT study and genetic counseling
  32. Canadian Thoracic Society (2025). Alpha-1-Antitrypsin Deficiency Targeted Testing and Augmentation Therapy: A Canadian Thoracic Society Meta-Analysis and Clinical Practice Guideline.Clinical guidance: COPD, adult-onset asthma with persistent obstruction, unexplained bronchiectasis
  33. Hamesch K, Strnad P (2020). Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency.Specialist clinical review: liver assessment, fibrosis and monitoring
  34. American Thoracic Society. Inhaled Marijuana and the Lungs.Respiratory-specialist patient guidance on inhaled cannabis and vulnerable lungs
  35. Manoukian A et al. (2013). Emission characteristics of air pollutants from incense and candle burning in indoor atmospheres. DOI: 10.1007/s11356-012-1394-y.Peer-reviewed experimental indoor study: VOC concentrations and particle-number emissions
  36. Ko YJ, National Research Council Canada (2021; revised 2022). CSC Smudging Toxicity: Literature Review.Government technical literature review: sage and other smudging materials, combustion products and fine particles
  37. US Environmental Protection Agency. Wood Smoke and Your Health.Public-health guidance: fine particles, toxic gases and asthma; archived Burn Wise resource
  38. Graves N, WHA expert Q&A, hosted by NIEHS. Protect Your Family’s Health: Keeping the Air Clean in Your Home.Expert educational Q&A: combustion, sage and palo santo; not a palo-santo-specific exposure experiment
  39. Health Canada (2025). Guidance for indoor air quality professionals.Technical guidance: indoor pollutants, source control and limitations of total-VOC measurements

Wondering whether you should be tested?

Start with the Alpha-1 Foundation’s Testing & Diagnosis page at alpha1.org. It explains who should consider testing and links to the Alpha-1 Coded Testing study, which currently offers free, confidential at-home testing through the University of Florida. You can also ask about genetic counseling before deciding to test.

Learn about Alpha-1 testing at alpha1.org